High rate of local control and cure at 10 years after treatment of prostate cancer with external beam radiotherapy and high-dose-rate brachytherapy: a single centre experience

References

• Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcome. Int J Radiat Oncol Biol Phys. 2008;1571:1028.
   Google Scholar
• Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464–473.
   PubMed Web of Science ®Google Scholar
• Heemsbergen WD, Al-Mamgani A, Slot A, et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110(1):104–109.
   PubMed Web of Science ®Google Scholar
• Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74.
   PubMed Web of Science ®Google Scholar
• Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010;28(7):1106–1111.
   PubMed Web of Science ®Google Scholar
• Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005;44(3):265–276.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Rojas AM, Bownes PJ, et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103(2):217–222.
   PubMed Web of Science ®Google Scholar
• Hsu I, Rodgers JP, Shinohara K, et al. Long-term results of NRG oncology/RTOG 0321: a phase II trial of combined high dose rate brachytherapy and external beam radiation therapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2020;110:700–707.
   PubMed Web of Science ®Google Scholar
• Martinez AA, Gonzalez J, Ye H, et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79(2):363–370.
   PubMed Web of Science ®Google Scholar
• Kälkner KM, Wahlgren T, Ryberg M, et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up. Acta Oncol. 2007;46(7):909–917.
   PubMed Web of Science ®Google Scholar
• Delahunt B, Egevad L, Samaratunga H, et al. Gleason and Fuhrman no longer make the grade. Histopathology. 2016;68(4):475–481. Review.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind CH, editors. International union against cancer. TNM classification of malignant tumours. 5th ed. New York (NY): John Wiley & Sons; 1997.
   Google Scholar
• Roach M, 3rd, Hanks G, Thames H, Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–974.
   PubMed Web of Science ®Google Scholar
• Gnanapragasam VJ, Bratt O, Muir K, et al. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: validation study. BMC Med. 2018;16(1):31.
   PubMedGoogle Scholar
• De Bari B, Daidone A, Alongi F. Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature. Crit Rev Oncol Hematol. 2015;94(3):360–370.
   PubMed Web of Science ®Google Scholar
• Prada PJ, González H, Fernández J, et al. Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience. BJU Int. 2012;109(12):1787–1793.
   PubMed Web of Science ®Google Scholar
• Galalae RM, Zakikhany NH, Geiger F, et al. The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer – a benchmark for high-tech external beam radiotherapy alone? J Brachy. 2014;13(2):117–122.
   PubMed Web of Science ®Google Scholar
• Åström L, Grusell E, Sandin F, et al. Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer. Radiother Oncol. 2018;127(1):81–87.
   PubMed Web of Science ®Google Scholar
• Ishiyama H, Kamitani N, Kawamura H, et al. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: an Asian Prostate HDR-BT Consortium. J Brachy. 2017;16(3):503–510.
   PubMed Web of Science ®Google Scholar
• Helou J, D’Alimonte L, Loblaw A, et al. High dose-rate brachytherapy boost for intermediate risk prostate cancer: long-term outcomes of two different treatment schedules and early biochemical predictors of success. Radiother Oncol. 2015;115(1):84–89.
   PubMed Web of Science ®Google Scholar
• Wedde TB, Småstuen MC, Brabrand S, et al. Ten-year survival after high-dose-rate brachytherapy combined with external beam radiation therapy in high-risk prostate cancer: a comparison with the Norwegian SPCG-7 cohort. Radiother Oncol. 2019;132:211–217.
   PubMed Web of Science ®Google Scholar
• Zelic R, Garmo H, Zugna D, et al. Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study. Eur Urol. 2020;77(2):180–188.
   PubMed Web of Science ®Google Scholar
• Galalae RM, Martinez A, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;1558(4):1048–1055.
   PubMed Web of Science ®Google Scholar